Eisai announced that NICE has given a positive recommendation for the use of lenvatinib in combination with everolimus to treat adults with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy, if their Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1. The company also provides lenvatinib
After failing to gain approval from UK cost watchdog, NICE, for the use of Halaven in treating breast cancer, Eisai has linked up with Valeant Pharmaceuticals International, to promote the drug in Central and Eastern Europe. Halaven received European Commission approval in March 2011. Valeant’s PharmaSwiss division will distribute Halaven (eribulin) in Bulgaria, Romania, Latvia,
Eisai has received mixed news this week, after news that Dacogen, Eisai and Astex Pharmaceuticals’ drug to treat a type of leukaemia, has been rejected by an independent advisory panel to the regulator in the USA. The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee voted 10 to 3 that statistics in Eisai’s
